Pharma Intermediates are chemical raw materials or intermediates products used in drug synthesis processes. From the development history of China's pharma intermediates industry, after nearly 30 years of development, pharma intermediates have developed from a small branch of the chemical industry into a new industry with an output value of tens of billions of RMB, and its market competition has become increasingly fierce. Below, we will introduce several common pharma intermediates for you.
N-benzyl-N-methyl ethanolamine is an important pharma intermediate, which can be used to synthesize anti-asthma and anti-allergy drugs, the antihypertensive drug nifedipine, and some new drugs for the treatment of cardiovascular diseases. It can also be used to synthesize pesticides, herbicides, and metal preservatives.
4,4' -dimethoxyacetyl acetone methyl ester is an important intermediate of the cardiovascular disease drug nifedipine, which is currently the dominant cardiovascular disease drug in the international market, but not yet produced in China. It is synthesized by reacting dimethoxyacetic acid methyl ester with sodium methoxide and acetic acid methyl ester in the presence of concentrated sulfuric acid.
α-methylene cyclohexanone is the active center of many anticancer drugs. Its α,β-unsaturated ketone structure is a concealed group of anticancer active groups, making it an important pharma intermediate for synthesizing many important cyclic anticancer drugs.
4-propylthio-o-phenylenediamine is a key pharma intermediate of albendazole, which is a new drug that was launched in the late 1980s. It has low toxicity to humans and animals and is the most potent anthelmintic among the benzimidazole drugs.
Pazopanib is a novel oral antiangiogenic inhibitor that interferes with the new blood vessel formation necessary for the survival and growth of refractory tumors. It targets vascular endothelial growth factor receptor (VEGFR) and works by inhibiting the new blood vessel formation that supplies the tumor. It is used to treat advanced renal cell carcinoma, soft tissue sarcoma (STS), epithelial ovarian cancer, and non-small cell lung cancer (NSCLC).